Scarica l'app Stockscreener
10.15
1.00%
0.10
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché KROS Giù?
Forum
Previsione
Precedente Chiudi:
$10.05
Aprire:
$10.1
Volume 24 ore:
178.21K
Relative Volume:
0.47
Capitalizzazione di mercato:
$200.89M
Reddito:
$244.06M
Utile/perdita netta:
$87.01M
Rapporto P/E:
5.5729
EPS:
1.8213
Flusso di cassa netto:
$105.95M
1 W Prestazione:
-1.46%
1M Prestazione:
-12.88%
6M Prestazione:
-52.81%
1 anno Prestazione:
-25.59%
Intervallo 1D:
$10.01
$10.47
Intervallo di 1 settimana:
$9.69
$10.47
Portata 52W:
$9.69
$22.55
Keros Therapeutics Inc Stock (KROS) Company Profile
Nome
Keros Therapeutics Inc
Settore
Industria
Telefono
617-314-6297
Indirizzo
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Compare KROS vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
10.15 | 200.89M | 244.06M | 87.01M | 105.95M | 1.8213 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-06-10 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-01-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | Downgrade | Wedbush | Outperform → Neutral |
| 2024-12-16 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-12-16 | Reiterato | Oppenheimer | Outperform |
| 2024-12-13 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-12 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-12-12 | Downgrade | TD Cowen | Buy → Hold |
| 2024-12-12 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | Iniziato | Jefferies | Buy |
| 2024-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-09-23 | Iniziato | Guggenheim | Buy |
| 2024-06-25 | Iniziato | Oppenheimer | Outperform |
| 2024-02-21 | Iniziato | William Blair | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-07-31 | Iniziato | Wedbush | Outperform |
| 2023-07-26 | Iniziato | BofA Securities | Buy |
| 2023-02-14 | Iniziato | Cowen | Outperform |
| 2022-10-18 | Iniziato | Truist | Buy |
| 2022-07-26 | Iniziato | BTIG Research | Buy |
| 2020-12-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-04 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-04 | Iniziato | Jefferies | Buy |
| 2020-05-04 | Iniziato | Piper Sandler | Overweight |
| 2020-05-04 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Keros Therapeutics Inc Borsa (KROS) Ultime notizie
Keros Therapeutics, Inc. Stock 12‑Month Price Target Cut to $20.2, Implies 99% Upside - TradingView
Keros Therapeutics Hits 52-Week Low at $9.69 Amidst Major Decline - MarketsMojo
KROS Q1 2026 Earnings: Wider-Than-Expected Loss as Pipeline AdvancesNon-GAAP Earnings - newsline.com
[144] Keros Therapeutics, Inc. SEC Filing - Stock Titan
Keros Therapeutics director Nima sells $28,166 in company stock By Investing.com - Investing.com Nigeria
KROS: KER-065 targets muscle regeneration in DMD, with strong early data and a solid financial runway - TradingView
Keros Therapeutics director Nima sells $28,166 in company stock - Investing.com
Director at Keros Therapeutics (NASDAQ: KROS) logs 2,625-share sale - Stock Titan
Director at Keros Therapeutics (KROS) sells 2,625 shares in Rule 10b5-1 trade - Stock Titan
Keros Therapeutics (KROS) Faces Selling Pressure as Shares Approach Key SupportATR Trailing Stop - newsline.com
How (KROS) Movements Inform Risk Allocation Models - Stock Traders Daily
Insider Sell: Alpna Seth Sells Shares of Keros Therapeutics Inc (KROS) - GuruFocus
Keros Therapeutics director granted RSUs and options | KROS Insider Trading - Stock Titan
Keros Therapeutics (KROS) director sells 2,625 shares under Rule 10b5-1 plan - Stock Titan
Keros Therapeutics (NASDAQ: KROS) director receives RSU and stock option awards - Stock Titan
Keros Therapeutics (KROS) grants RSUs and stock options to director - Stock Titan
Keros Therapeutics (NASDAQ: KROS) director receives RSUs and options grant - Stock Titan
Keros Therapeutics (KROS) director awarded RSUs and stock options - Stock Titan
Keros Therapeutics Stockholders Approve Directors and Governance Matters - TipRanks
Keros Therapeutics (NASDAQ: KROS) backs directors, auditor and pay - Stock Titan
Keros Therapeutics, Inc. Stock 12‑Month Price Target Cut to $21.83, Implies 107% Upside - TradingView
Keros Therapeutics CEO to Present at Goldman Sachs Conference - The Globe and Mail
Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference - The Manila Times
Keros Therapeutics CEO to speak at Goldman Sachs health conference - Stock Titan
Keros Therapeutics (Nasdaq: KROS) CEO to join Goldman Sachs healthcare fireside chat - Stock Titan
KROS Q1 2026 Earnings: EPS Miss of $1.21 as Pre-Revenue Biotech Continues Clinical InvestmentTech Earnings Analysis - newsline.com
Keros Therapeutics (KROS) Edges Lower Near Key Support ZoneDescending Triangle - The Legal Advocate
Keros Therapeutics (KROS) Edges Higher Amid Consolidation Near Key ResistanceResistance Breakout Stocks - The Legal Advocate
Trading Systems Reacting to (KROS) Volatility - Stock Traders Daily
Keros Therapeutics (KROS) Edges Higher as Biotech Sector Shows Mixed SignalsVirgin POC - newsline.com
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
KROS Turns to Next Wave of TGF-Beta Muscle Therapies - The Globe and Mail
Should You Buy KROS After Q1 Miss and Takeda Deal Reset? - The Globe and Mail
KROS Stock Guide to Rinvatercept in DMD and ALS for 2026 - The Globe and Mail
Keros Therapeutics (KROS) Q1 2026 Disappoints — EPS $-1.21 Below $-1.04 ViewsQuarterly Earnings Report - Newser
Keros Therapeutics, Inc. (KROS) reports Q1 loss, misses revenue estimates - MSN
Lexington, MA Biotech Pushes DMD Phase 2 Start to 3Q26 on Regulatory Hurdles - Streetwise Reports
Lexington, MA Biopharma Co. Reports Q1 2026 Financials, Makes R&D Plans - Streetwise Reports
Wedbush Maintains Keros Therapeutics(KROS.US) With Hold Rating, Maintains Target Price $16 - Moomoo
Director at Keros Therapeutics (KROS) buys 1,000 shares under 10b5-1 plan - Stock Titan
Why is Keros Therapeutics (KROS) up 2.5% since last earnings report? - MSN
Keros Therapeutics, Inc.common stock (NQ: KROS - The Chronicle-Journal
Earnings Release: Here's Why Analysts Cut Their Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target To US$21.20 - Yahoo Finance
How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24% - MSN
Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating - Moomoo
A Quick Look at Today's Ratings for Keros Therapeutics(KROS.US), With a Forecast Between $20 to $20 - Moomoo
Nantahala's 1.36M-share stake in Keros Therapeutics (NASDAQ: KROS) - Stock Titan
Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year - The Globe and Mail
Keros Therapeutics Reports Q1 2026 Financial Results: Net Loss, Cash Position, and R&D Updates - Minichart
Keros Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
KROS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Keros Therapeutics Inc Azioni (KROS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Keros Therapeutics Inc Azioni (KROS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Farzan Nima | Director |
Jun 04 '26 |
Sale |
10.73 |
2,625 |
28,166 |
9,767 |
| Knowles Julius | Director |
Jun 04 '26 |
Sale |
10.73 |
2,625 |
28,166 |
10,958 |
| Seth Alpna | Director |
Jun 04 '26 |
Sale |
10.72 |
2,625 |
28,140 |
9,767 |
1.04%
0.76%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):